Histone

Gene

Biology

Dasatinib

Proteolysis

Ubiquitin ligase

Receptor

Signal transduction

Bromodomain

Biochemistry

DNA ligase

Ubiquitin

Computational biology

Drug discovery

Combinatorial chemistry

Ligand (biochemistry)

Organic chemistry

Tyrosine kinase

Enzyme

BRD4

Chemistry

Covalent bond

Journal of the American Chemical Society

Proteolysis-targeting chimeras (PROTACs), heterobifunctional compounds that consist of protein-targeting ligands linked to an E3 ligase recruiter, have arisen as a powerful therapeutic modality for targeted protein degradation (TPD). Despite the popularity of TPD approaches in drug discovery, only a small number of E3 ligase recruiters are available for the >600 E3 ligases that exist in human cells. Here, we have discovered a cysteine-reactive covalent ligand, EN106, that targets FEM1B, an E3 ligase recently discovered as the critical component of the cellular response to reductive stress. By targeting C186 in FEM1B, EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. We further establish that EN106 can be used as a covalent recruiter for FEM1B in TPD applications by demonstrating that a PROTAC linking EN106 to the BET bromodomain inhibitor JQ1 or the kinase inhibitor dasatinib leads to the degradation of BRD4 and BCR-ABL, respectively. Our study showcases a covalent ligand that targets a natural E3 ligase–substrate binding site and highlights the utility of covalent ligand screening in expanding the arsenal of E3 ligase recruiters suitable for TPD applications.

Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications